Annals of Emergency Medicine
Volume 44, Issue 1 , Pages 12-19, July 2004

Delta creatine kinase–MB outperforms myoglobin at two hours during the emergency department identification and exclusion of troponin positive non–ST-segment elevation acute coronary syndromes☆☆★★

From the Heart and Stroke Center (Fesmire) and Department of Pathology (Fody, Feintuch), Erlanger Medical Center, University of Tennessee College of Medicine, Chattanooga, TN; and the Departments of Pathology and Medical and Research Technology, University of Maryland School of Medicine, Baltimore, MD (Christenson) USA

Received 2 October 2003; received in revised form 22 December 2003 and 5 February 2004; accepted 6 February 2004.

Abstract 

Study objective

Limited information is available about the diagnostic performance of creatine kinase (CK)–MB and myoglobin levels during the early evaluation of chest pain patients using cardiac troponins as the criterion standard for diagnosing acute myocardial infarction. In this study, we compare the sensitivity and specificity of the baseline, 2-hour absolute, and 2-hour delta values of myoglobin and CK-MB mass assay for detection of acute myocardial infarction using cardiac troponin I (troponin) as the sole marker of myocardial necrosis.

Methods

A prospective observational study was conducted of 975 chest pain patients with a baseline troponin level of 1.0 ng/mL or less (Abbott Axsym Assay) and an initial ECG nondiagnostic for injury. CK-MB, myoglobin, and troponin levels were all measured on the Abbott Axsym immunoassay. Acute myocardial infarction was diagnosed if there was at least 20 minutes of chest pain and any one of the following criteria within 24 hours of ED presentation: a serial increase in troponin to more than 1.0 ng/mL, new Q-wave formation in 2 contiguous leads, or patient death by cardiac or unknown cause. The optimal values of CK-MB and myoglobin were chosen at the most accurate value on the receiver operating characteristic (ROC) curve (ie, value with lowest false-negative and false-positive rate) of the 2-hour absolute and 2-hour delta value for predicting acute myocardial infarction.

Results

Acute myocardial infarction was diagnosed in 44 (4.5%) of the 975 study patients. ROC curve analysis revealed no statistically significant differences in areas for myoglobin and CK-MB values at baseline and 2 hours for determination of acute myocardial infarction. However, the ROC curve area of the delta CK-MB level significantly outperformed the ROC curve area of the delta myoglobin level for early identification of acute myocardial infarction (0.97 versus 0.81; 95% confidence interval [CI] for difference between areas 0.09 to 0.24). At the most accurate cutoff value, a 2-hour delta CK-MB level more than 0.7 ng/mL had a sensitivity of 93.2% (95% CI 81.3% to 98.5%), a specificity of 94.4% (95% CI 92.7% to 95.8%), a positive likelihood ratio of 16.7, and a negative likelihood ratio of 0.07.

Conclusion

A 2-hour delta CK-MB level outperforms myoglobin level in the early identification and exclusion of acute myocardial infarction in non–ST-segment elevation chest pain patients. This finding suggests that myoglobin may no longer be the optimal early marker of acute myocardial infarction when troponins are used as the criterion standard.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Author contributions: FMF conceived the study and obtained research funding. All authors were involved in conception and design of the study. FMF and RHC were responsible for analysis and interpretation of data. FMF drafted the manuscript, and all authors contributed substantially to its revision. FMF takes responsibility for the paper as a whole.

☆☆ Presented at the American College of Emergency Physicians Research Forum, Seattle, WA, October 15, 2002.

 Supported by unrestricted research grants from Phillips Medical Systems (formerly Hewlett-Packard), Millennium Pharmaceuticals Inc. (formerly Cor Therapeutics), Bristol-Myers Squibb Medical Imaging (formerly DuPont RadioPharmaceuticals), and EmCare, Inc.

★★ Reprints not available from the authors.

PII: S0196-0644(04)00094-0

doi:10.1016/j.annemergmed.2004.02.003

Annals of Emergency Medicine
Volume 44, Issue 1 , Pages 12-19, July 2004